COVID-19 Response

Dear Exactis Network, 
With the current and ever-evolving situation with COVID-19, we wanted to provide you with an update on our response to date and our commitment moving forward. The health, safety and well-being of participants, and our Network Team is a top priority. We are following the lead of Canadian and provincial public health authorities at this time and have been in touch daily with our site leads.

Exactis, with the guidance and assistance of Dr. Gerald Batist (Exactis’ Chief Medical Officer), our PI Coordinating Committee (PICC) Chairs (Drs. Helen MacKay and Quincy Chu) and Exactis Leadership, will be meeting to develop a COVID-19 action plan regarding our activities and projects on Friday, March 27.  The plan will be communicated via the PICC early next week.  

We continue to monitor and align with guidance from Health Canada and provincial health authorities while working in coordination with our Network sites to support the continuity of the Personalize my Treatment (PMT) registry and associated projects. We are also looking at opportunities in which we can safely deploy our workforce to help in better defining the medical, social and economic impact of COVID-19 specifically in the cancer patient community.

Current Guidance to the Network

To reduce the risk to our stakeholders, we have temporarily put a hold on new patient screenings and enrollment in the PMT registry across the Network sites. We are aware that PMT Coordinators are working remotely from home and most sites have enabled remote access to source data. At this time, the PMT Coordinators will focus on clinical data entry and updating the Registry.  The Exactis team will continue to support the PMT Coordinators by performing remote monitoring and by providing direction. 

As we make every effort to work with you to minimize the impact of COVID-19 on the network, we know that there will be challenges ahead and we look forward to working through these together.  
For questions or additional information on Exactis’ COVID-19 response during this unprecedented time, please do not hesitate to contact Mathilde Couetoux du Tertre at